Expression and clinicopathologic significance of OPN, CD44v6 and MMP-2 in squamous cell carcinoma and adenocarcinoma of the lung

Chinese Journal of Lung Cancer

Volumn 9, Issue 4, 2006, Pages 325-328

  Yu, Jun ^a   Pan, Tiecheng ^a   Li, Jun ^a   Wei, Xiang ^a   Chen, Tao ^a   Hu, Min ^a   Song, Dingwei ^a   Liu, Ligang ^a   Chen, Peng ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

CD44V6; Immunohistochemistry; Lung neoplasms adenocarcinoma; Lung neoplasms squamous cell carcinoma; MMP 2; OPN

Indexed keywords

CD44V6 ANTIGEN; GELATINASE A; OSTEOPONTIN;

ARTICLE; CANCER GROWTH; CANCER INVASION; CANCER STAGING; CELL DIFFERENTIATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG SQUAMOUS CELL CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PROTEIN EXPRESSION;

EID: 33748118745     PISSN: 10093419     EISSN: 19996187     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Denhardt DT, Giachelli CM, Rittling SR. Role of osteopontin in cellular signaling and toxicant injury. Annu Rev Pharmacol Toxicol, 2001, 41: 723-749.
2. Weber GF, Ashkar S, Glimcher MJ, et al. Receptor-ligand interaction between CD44 and osteopontin (Eta-1). Science, 1996, 271 (5248): 509-512.
3. Haynes BF, Liao HX, Patton KL. The transmembrane hyaluronate receptor (CD44): multiple functions, multiple forms. Cancer Cells, 1991, 3(9): 347-350.
4. Stetler-Stevenson WG, Liotta LA, Kleiner DE Jr. Extracellular matrix 6: role of matrix metalloproteinases in tumor invasion and metastasis. FASEB J, 1993, 7(15): 1434-1441.
5. Zhang J, Takahashi K, Takahashi F, et al. Differential osteopontin expression in lung cancer. Cancer Lett, 2001, 171(2): 215-222.
6. Shijubo N, Uede T, Kon S, et al. Vascular endothelial growth factor and osteopontin in stage I lung adenocarcinoma. Am J Respir Crit Care Med, 1999, 160(4): 1269-1273.
7. Pan HW, Ou YH, Peng SY, et al. Overexpression of osteopontin is associated with intrahepatic metastasis, early recurrence, and poorer prognosis of surgically resected hepatocellular carcinoma. Cancer, 2003, 98(1): 119-127.
8. Gao C, Guo H, Downey L, et al. Osteopontin-dependent CD44v6 expression and cell adhesion in HepG2 cells. Carcinogenesis, 2003, 24(12): 1871-1878.
9. Hefler LA, Concin N, Mincham D, et al. The prognostic value of immunohistochemically detected CD44v3 and CD44v6 expression in patients with surgically staged vulvar carcinoma: a multicenter study. Cancer, 2002, 94(1): 125-130.
10. Kleiner DE, Stetler-Stevenson WG. Matrix metalloproteinases and metastasis. Cancer Chemother Pharmacol. 1999, 43(Suppl): S42-S51.
11. Jiang DF, Lu YL, Qiu ZY, et al. Study on differentially expressed molecules influencing the metastatic potential between highly and poorly metastatic human lung giant cell carcinoma. Chin J Oncol, 2003, 25(6): 531-534.
12. Yuan LX, He WM, Zhang B, et al. Is the expression of MMP-2, MMP-9, TIMP-2 related to metastasis and recurrence of breast cancer? Tumor, 2002, 22(4): 294-296.
13. Li HM, Fang WG, Zheng J, et al. Zymographic analysis of MMPs in human carcinoma cell lines with different metastasis potential. Chin J Pathol, 1998, 27(5): 341-343.
14. Zucker S, Lysik RM, Malik M, et al. Secretion of gelatinases and tissue inhibitors of metalloproteinases by human lung cancer cell lines and revenant cell lines: not an invariant correlation with metastasis. Int J Cancer, 1992, 52(3): 366-371.
15. Gonzalez-Avila G, Iturria C, Vadillo F, et al. 72-kD (MMP-2) and 92-kD (MMP-9) type IV collagenase production and activity in different histologic types of lung cancer cells. Pathobiology, 1998, 66(1): 5-16.
16. Lin Q, Wang LX. The progress of the study on the relationship of the OPN and blood vessel remodeling. Med Recapitulate, 2004, 10 (12): 731-733.
17. Chambers AF, Wilson SM, Kerkvliet N, et al. Osteopontin expression in lung cancer. Lung Cancer, 1996, 15(3): 311-323.